Author:
Murakami Koji,Tamada Tsutomu,Saigusa Daisuke,Miyauchi Eisaku,Nara Masayuki,Ichinose Masakazu,Kurano Makoto,Yatomi Yutaka,Sugiura Hisatoshi
Abstract
AbstractSince the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.
Funder
Japan Society for Science and Promotion of Science
GSK Japan Research Grant 2017
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Hunninghake, G. W. et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis. Vasc. Diffuse Lung Dis. 16, 149–173 (1999).
2. Iannuzzi, M. C., Rybicki, B. A. & Teirstein, A. S. Sarcoidosis. N. Engl. J. Med. 357, 2153–2165. https://doi.org/10.1056/NEJMra071714 (2007).
3. Nagai, S. et al. Outcome of sarcoidosis. Clin. Chest Med. 29(565–574), x. https://doi.org/10.1016/j.ccm.2008.03.006 (2008).
4. Iannuzzi, M. C. & Fontana, J. R. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 305, 391–399. https://doi.org/10.1001/jama.2011.10 (2011).
5. Chopra, A., Kalkanis, A. & Judson, M. A. Biomarkers in sarcoidosis. Expert. Rev. Clin. Immunol. 12, 1191–1208. https://doi.org/10.1080/1744666X.2016.1196135 (2016).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 多様な臓器病変とサルコイドーシスの病態に関する臨床的検討;The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders;2023-10-01
2. Lysophospholipids and their producing enzymes: Their pathological roles and potential as pathological biomarkers;Pharmacology & Therapeutics;2023-06
3. Role of autotaxin in systemic lupus erythematosus;Frontiers in Medicine;2023-04-04
4. II. Sarcoidosis;Nihon Naika Gakkai Zasshi;2022-10-10
5. Renal sarcoidosis;Nephrology Dialysis Transplantation;2022-07-22